Siemens medical technology sales down 13% in first half:
This article was originally published in Clinica
Medtech remains one of Siemens problems as other parts of the German conglomerate's business have shown strong growth in the first half of fiscal 1995 to the end of March. Medtech reported a 13% decline in first-half sales to DM 3,200 million ($2,336 million). New orders fell 12% compared with the previous year. Siemens' group turnover, on the other hand, rose 5% to DM 40,000 million, with all growth coming from domestic business at a time when international sales were dampened by the strong German mark. Net income increased 7% to DM 939 million. Siemens warns that the appreciation of the mark could thwart the company's aim to increase profits by 20% in fiscal 1995.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.